Recent observation has shown that VMAT-2 is also involved in attention deficit hyperactivity disorder (ADHD), which is characterized by changes in executive function and cognitive deficits (Iv et al., 2024), and, accordingly, TBZ was applied for their treatment recently (Porta et al., 2008). Here, SLC18A2 is linked to attention deficit-hyperactivity disorder.